Show simple item record

Article

dc.creatorLópez Siguero, Juan P.es
dc.creatorMartínez Aedo, María J.es
dc.creatorBermúdez de la Vega, José Antonioes
dc.creatorBosh Muñoz, Jordies
dc.creatorLechuga Sancho, Alfonso M.es
dc.creatorVillalobos, Trianaes
dc.date.accessioned2022-09-21T09:53:58Z
dc.date.available2022-09-21T09:53:58Z
dc.date.issued2022
dc.identifier.citationLópez Siguero, J.P., Martínez Aedo, M.J., Bermúdez de la Vega, J.A., Bosh Muñoz, J., Lechuga Sancho, A.M. y Villalobos, T. (2022). Growth hormone treatment does not to lead to insulin resistance nor excessive rise in IGF-1 levels, while improving height in patients small for gestational age A long-term observational study. Clinical Endocrinology, 96 (4), 558-568.
dc.identifier.issn0300-0664es
dc.identifier.issn1365-2265es
dc.identifier.urihttps://hdl.handle.net/11441/137252
dc.description.abstractObjective :In children born small for gestational age (SGA), the relationship betweengrowth hormone (GH) treatment and insulin resistance (IR) has only been investigated fora short period, necessitating a longer observation period. This study aimed to evaluate thelong‐term (10 years) effect of GH to SGA‐children on IR and safety during treatment.Design:This was a multicenter observational study.Patients:SGA‐children who received GH treatment in Spain (stratified by Tanner‐stage and age at GH onset [two groups:≤6 years old or >6 years old]).Measurements:The analysed variables (yearly measures) included auxologic, meta-bolic (insulin‐like growth factor‐1 (IGF‐1), height velocity [HV], weight and homeo-static model assessment‐IR [HOMA‐IR]) and safety data. Data were collectedprospectively (since the study approval: 2007) and retrospectively (since the initia-tion of GH treatment: 2005–2007).Results:A total of 389 SGA children (369 Tanner‐I) were recruited from 27 centres.The mean age (standard deviation) of the children at GH treatment onset was 7.2(2.8) years old. IGF‐1 (standard deviation score [SDS]) and HOMA‐IR values tendedto increase until the sixth year of GH‐treatment, with significant differences beingobserved only during the first year, while these remained stable in the later years(within normal ranges). Height (SDS) increased significantly (basal:−3.0; tenthyear:−1.13), and the maximum HV (SDS) occurred during the first year (2.75 ± 2.39).Conclusions:HOMA‐IR values increased significantly in SGA‐children during thefirst year of GH‐treatment, remained stable and were within normal ranges in allcases. Our 10‐year data suggests that long‐term GH treatment does not promote IRand is well‐tolerated, safe and effective.es
dc.formatapplication/pdfes
dc.format.extent11 p.es
dc.language.isoenges
dc.publisherWiley-Blackwell Publishing, Inc.es
dc.relation.ispartofClinical Endocrinology, 96 (4), 558-568.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectEfficacyes
dc.subjectGrowth hormonees
dc.subjectHomeostatic model assessmentes
dc.subjectInsulin resistancees
dc.subjectLong-term follow-upes
dc.subjectSafetyes
dc.subjectSmall for gestational agees
dc.titleGrowth hormone treatment does not to lead to insulin resistance nor excessive rise in IGF-1 levels, while improving height in patients small for gestational age A long-term observational studyes
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Farmacología, Pediatría y Radiologíaes
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/doi/10.1111/cen.14626es
dc.identifier.doi10.1111/cen.14626es
dc.journaltitleClinical Endocrinologyes
dc.publication.volumen96es
dc.publication.issue4es
dc.publication.initialPage558es
dc.publication.endPage568es

FilesSizeFormatViewDescription
Growth hormone treatment.pdf748.3KbIcon   [PDF] View/Open  

This item appears in the following collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as: Attribution-NonCommercial-NoDerivatives 4.0 Internacional